Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors.
Laryngoscope
; 113(7): 1231-7, 2003 Jul.
Article
en En
| MEDLINE
| ID: mdl-12838025
ABSTRACT
OBJECTIVES/HYPOTHESIS:
The extra domain B (ED-B) of fibronectin, a naturally occurring marker of tissue remodeling and angiogenesis, is expressed in the majority of aggressive solid human tumors, whereas it is not detectable in normal vessels and tissues. STUDYDESIGN:
In view of the diagnostic and therapeutic clinical applications of the L19 antibody, which is specific for the ED-B domain of fibronectin, a prospective immunohistochemical analysis of different head and neck tumors was performed.METHODS:
In all, 82 head and neck tissue biopsy specimens were immunohistochemically analyzed using the L19 antibody. They consisted of 53 different malignant tumors, 8 benign tumors, 10 nontumoral lesions, and 11 normal control tissues.RESULTS:
A strong positive staining with the L19 antibody could be observed in 87% of the investigated malignant tumors, in only 38% of the benign tumors, and in 20% of the nontumoral lesions (P <.0001). The extra domain B was completely absent in the normal control tissue samples.CONCLUSIONS:
The results show that ED-B is abundantly expressed around the neovasculature and in the stroma of the majority of malignant tumors of the head and neck but is undetectable in normal tissues. The ED-B domain of fibronectin is a good-quality tumor-stroma-associated antigen that warrants clinical trials with antibody-based pharmaceuticals, including immunoscintigraphic investigations and radioimmunoguided surgery with the radiolabeled L19 antibody.
Buscar en Google
Colección:
01-internacional
Asunto principal:
Fibronectinas
/
Neoplasias de Cabeza y Cuello
/
Neovascularización Patológica
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
En
Revista:
Laryngoscope
Asunto de la revista:
OTORRINOLARINGOLOGIA
Año:
2003
Tipo del documento:
Article
País de afiliación:
Suiza